Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Global Cord Blood Corporation Reports Financial Results for the Second Quarter and First Half of Fiscal 2022


      News provided by

      Global Cord Blood Corporation

      Nov 24, 2021, 16:16 ET

      Share this article

      Share this article


      Added 19,066 New Subscribers in 2Q22
      Revenues Up 9.8% YoY to RMB313.7 Million ($48.7 Million)        
      Gross Profit Up 11.0% YoY to RMB267.5 Million ($41.5 Million)
      Operating Income Up 15.3% YoY to RMB160.5 Million ($24.9 Million)
      Non-GAAP Operating Income Up 14.1% YoY to RMB172.8 Million ($26.8 Million)
      Conference Call to be Held on November 26, 2021, at 8:00 a.m. ET

      HONG KONG, Nov. 24, 2021 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced its unaudited financial results for the second quarter and first half of fiscal 2022 ended September 30, 2021.

      Second Quarter of Fiscal 2022 Highlights

      • Revenues increased by 9.8% year-over-year ("YoY") to RMB313.7 million ($48.7 million).
      • New subscribers and accumulated subscriber base were 19,066 and 938,092[1], respectively.
      • Gross profit increased by 11.0% YoY to RMB267.5 million ($41.5 million). Gross margin increased to 85.3% from 84.3% in the prior year period.
      • Operating income increased by 15.3% YoY to RMB160.5 million ($24.9 million). Operating margin increased to 51.2% from 48.7% in the prior year period.
      • Operating income before depreciation and amortization ("non-GAAP operating income[2]") increased by 14.1% YoY to RMB172.8 million ($26.8 million).
      • Net income attributable to the Company's shareholders decreased by 4.3% YoY to RMB125.7 million ($19.5 million), mainly due to the decrease in fair value of equity securities ("mark-to-market loss") and the absence of dividend income.
      • Net cash provided by operating activities was RMB157.0 million ($24.4 million).

      First Half of Fiscal 2022 Highlights

      • Revenues increased by 11.0% YoY to RMB628.8 million ($97.6 million).
      • New subscribers and accumulated subscriber base were 38,739 and 938,092[1], respectively.
      • Gross profit increased by 11.8% YoY to RMB534.8 million ($83.0 million).
      • Operating income increased by 16.3% YoY to RMB317.0 million ($49.2 million).
      • Non-GAAP operating income[2] increased by 14.8% YoY to RMB341.3 million ($53.0 million).
      • Net income attributable to the Company's shareholders decreased by 0.7% to RMB262.2 million ($40.7 million), mainly due to mark-to-market loss of equity securities.
      • Net cash provided by operating activities was RMB329.8 million ($51.2 million).

      "Despite the uncertainty of industry-related regulation, long-standing challenges of China's population structure, and lingering effects from the COVID-19 pandemic, we managed to recruit 19,066 new subscribers in the second quarter of fiscal 2022, in line with management's expectations," said Ms. Ting Zheng, Chairperson and Chief Executive Officer of GCBC. "As we continue to monitor relevant regulations and carry on with our organic growth efforts, we have directed ample resources to analyze business development opportunities in-depth to foster the long-term growth of the Company."

      Summary – Second Quarter and First Half Ended September 30, 2020 and 2021



      Three Months Ended September 30,


      Six Months Ended September 30,



      2020


      2021


      2020


      2021

      (in thousands)


      RMB


      RMB


      US$


      RMB


      RMB


      US$

      Revenues


      285,607


      313,670


      48,681


      566,520


      628,844


      97,595

      Gross Profit


      240,909


      267,461


      41,509


      478,359


      534,794


      82,999

      Operating Income[3]


      139,161


      160,452


      24,902


      272,670


      317,008


      49,199

      Change in Fair Value of   


      5,699


      (12,616)


      (1,958)


      24,104


      (7,015)


      (1,089)

        Equity Securities













      Dividend Income


      1,281


      -


      -


      1,281


      1,120


      174

      Net Income Attributable to
        the Company's
        Shareholders


      131,434


      125,736


      19,515


      263,943


      262,157


      40,686

      Earnings per Ordinary













        Share (RMB/US$)    













        – Basic   


      1.08


      1.03


      0.16


      2.17


      2.15


      0.33

        – Diluted


      1.08


      1.03


      0.16


      2.17


      2.15


      0.33














      Revenues Breakdown (%)













      Processing Fees and Other

        Services


      57.5%


      57.5%




      57.5%


      58.0%



      Storage Fees


      42.5%


      42.5%




      42.5%


      42.0%
















      New Subscribers (persons)


      17,643


      19,066




      34,876


      38,739



      Total Accumulated
        Subscribers (persons)


      867,180


      938,092[1]




      867,180


      938,092[1]



      Summary – Selected Cash Flow Statement Items



      Three Months Ended September 30,


      Six Months Ended September 30,



      2020


      2021


      2020


      2021

      (in thousands)


      RMB


      RMB


      US$


      RMB


      RMB


      US$

      Net cash provided by
       
      operating activities


      174,814


      156,976


      24,364


      274,643


      329,799


      51,186

      Net cash used in













       investing activities


      (3,876)


      (3,687)


      (572)


      (11,320)


      (6,233)


      (967)

      Net cash used in













       financing activities


      (6,074)


      -


      -


      (6,074)


      (7,729)


      (1,200)

      Second Quarter of Fiscal 2022 Financial Results

      REVENUES. Revenues increased by 9.8% YoY to RMB313.7 million ($48.7 million) in the second quarter of fiscal 2022, as a result of the increase in processing fees from new subscribers and growth in storage fee revenues.

      The Company recruited 19,066 new subscribers during the reporting quarter, an increase of 8.1% YoY, partially due to the lower subscriber base in the prior year period. Revenues generated from processing fees and other services increased by 9.7% YoY to RMB180.3 million ($28.0 million), representing 57.5% of total revenues, same as in the prior year period.

      The accumulated subscriber base as of September 30, 2021 expanded to 938,092[1]. Revenues generated from storage fees in the reporting quarter increased by 10.0% YoY to RMB133.4 million ($20.7 million).

      GROSS PROFIT. Gross profit for the second quarter increased by 11.0% YoY to RMB267.5 million ($41.5 million) and gross margin increased to 85.3% from 84.3% in the prior year period as efficiency gain outpaced rising labor cost.

      OPERATING INCOME. Topline improvement and postponing various sales and marketing activities lifted operating income. Operating income for the second quarter increased by 15.3% YoY to RMB160.5 million ($24.9 million). Operating margin improved to 51.2% from 48.7% in the prior year period. Depreciation and amortization expenses were RMB12.4 million ($1.9 million), compared to RMB12.3 million in the prior year period. Non-GAAP operating income[2] increased by 14.1% YoY to RMB172.8 million ($26.8 million).

      Research and Development Expenses. Research and development expenses increased to RMB5.6 million ($0.9 million) from RMB5.0 million in the prior year period.

      Sales and Marketing Expenses. Sales and marketing expenses increased by 5.2% YoY to RMB56.9 million ($8.8 million), as staff related expenses grew while the Company continued to hold back some marketing and promotional activities. Sales and marketing expenses as a percentage of revenues decreased to 18.1% from 19.0% in the prior year period and 18.8% in the prior quarter.

      General and Administrative Expenses. General and administrative expenses amounted to RMB44.5 million ($6.9 million) compared to RMB42.7 million in the prior year period. The increase was led by higher staff costs. General and administrative expenses as a percentage of revenues decreased to 14.2% from 14.9% in the prior year period.

      OTHER INCOME AND EXPENSES. In the reporting period, the Company recognized a mark-to-market loss of RMB12.6 million ($2.0 million), compared to a mark-to-market gain of RMB5.7 million in the prior year period. The changes were attributable to the Company's investments in equity securities. In addition, no dividend was recorded in the reporting quarter, whereas RMB1.3 million dividend was recorded in the prior year period.

      NET INCOME ATTRIBUTABLE TO THE COMPANY'S SHAREHOLDERS. As the increase in operating income offset by the mark-to-market loss of equity securities, income before income tax for the reporting quarter slightly increased by 0.1% YoY to RMB156.4 million ($24.3 million). Income tax expense was RMB28.3 million ($4.4 million). Net income attributable to the Company's shareholders decreased by 4.3% YoY to RMB125.7 million ($19.5 million). Net margin for the second quarter was 40.1%.

      EARNINGS PER SHARE. Basic and diluted earnings per ordinary share for the second quarter of fiscal 2022 was RMB1.03 ($0.16).

      First Half of Fiscal 2022 Financial Results

      Total revenues for the first half of fiscal year 2022 increased by 11.0% YoY to RMB628.8 million ($97.6 million) as the number of new subscribers continued to improve from the COVID-induced low base in the prior year period and the enlarged accumulated subscriber base. Revenues from processing fees and other services increased by 12.0% YoY to RMB364.9 million ($56.6 million) and revenues from storage fees increased by 9.7% YoY to RMB263.9 million ($41.0 million). Gross profit increased by 11.8% YoY to RMB534.8 million ($83.0 million). Operating income increased by 16.3% YoY to RMB317.0 million ($49.2 million). Non-GAAP operating income[2] increased by 14.8% YoY to RMB341.3 million ($53.0 million). Net income attributable to the Company's shareholders decreased by 0.7% to RMB262.2 million ($40.7 million). Basic and diluted earnings per ordinary share was RMB2.15 ($0.33). Net cash provided by operating activities improved by 20.1% YoY to RMB329.8 million ($51.2 million), partially due to a lower base in the prior year period.

      Corporate Developments

      • On March 2, 2021, the Board of Directors of the Company (the "Board") received a non-binding proposal letter (the "Alternate Ocean Offer") from Alternate Ocean Investment Company Limited ("Alternate Ocean"), pursuant to which Alternate Ocean, acting on behalf of certain funds and/or entities (the "Acquirer") that it manages and/or advises, proposed to acquire all of the outstanding ordinary shares of the Company for $5.00 per ordinary share in cash, subject to certain conditions.
      • On March 15, 2021, the Board announced it had formed a special committee of independent directors who are not affiliated with Alternate Ocean (the "Special Committee") to evaluate the Alternate Ocean Offer. The Special Committee consists of Mr. Mark D. Chen, Dr. Ken Lu, Mr. Jack Chow, and Mr. Jacky Cheng, each of whom currently serves as an independent director on the Board with Mr. Chen serving as the chair of the Special Committee.
      • The Company cautions its shareholders and others considering trading its ordinary shares that no decisions have been made with respect to the Company's response to the proposed transaction. The proposed transaction is still subject to various conditions, including but not limited to, completion of due diligence, parties entering into definitive agreement, and/or the Acquirer and the Company each obtaining the relevant regulatory and shareholders' approval. There can be no assurance that any definitive offer will be made, that any agreement will be executed, or that this or any other transaction will be approved or consummated.

      Conference Call

      The Company will host a conference call at 8:00 a.m. ET on Friday, November 26, 2021, to discuss its financial performance and give a brief overview of the Company's recent developments, followed by a question and answer session. Interested parties can access the audio webcast through the Company's IR website at http://ir.globalcordbloodcorp.com. A replay of the webcast will be accessible two hours after the conference call and available for seven days at the same URL above. Listeners can also access the call by dialing 1-646-722-4977 or 1-855-824-5644 for US callers, or +852-3027-6500 for Hong Kong callers, access code: 14958969#.


      [1] During the three months and six months ended September 30, 2021, 19,066 and 38,739 new subscribers were recruited. During the three months and six months ended September 30, 2021, the Company determined that the recoverability of 1,169 and 2,084 private cord blood units was remote and therefore, the Company terminated their subscription services according to the subscription contracts. Out of these prior private cord blood units, 969 and 1,684 prior private cord blood units were being treated as if they were donated cord blood units and will be part of the Company's non-current inventories. Hence, the net accumulated subscriber base was 938,092 as of September 30, 2021.

      [2] See exhibit 3 to this press release for a reconciliation of non-GAAP operating income to exclude the non-cash items related to the depreciation and amortization expenses to the comparable financial measure prepared in accordance with U.S. generally accepted accounting principles ("U.S. GAAP").

      [3] The reported operating income for the three months ended September 30, 2020 and 2021 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB12.3 million and RMB12.4 million ($1.9 million), respectively. The reported operating income for the six months ended September 30, 2020 and 2021 included depreciation and amortization expenses related to property, plant and equipment and intangible assets of RMB24.6 million and RMB24.3 million ($3.8 million), respectively.

      Use of Non-GAAP Financial Measures

      GAAP results for the three months and six months ended September 30, 2021 include non-cash items related to depreciation and amortization expenses. To supplement the Company's unaudited condensed consolidated financial statements presented on a U.S. GAAP basis, the Company has provided adjusted financial information excluding the impact of these items in this press release. The non-GAAP financial measure represents non-GAAP operating income. Such adjustment is a departure of U.S. GAAP; however, the Company's management believes that these adjusted measures provide investors with a better understanding of how the results relate to the Company's historical performance. Also, management uses non-GAAP operating income as a measurement tool for evaluating actual operating performance compared to budget and prior periods. These adjusted measures should not be considered an alternative to operating income, or any other measure of financial performance or liquidity presented in accordance with U.S. GAAP. These measures are not necessarily comparable to a similarly titled measure of another company. A reconciliation of the adjustments to U.S. GAAP results appears in exhibit 3 accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for U.S. GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

      About Global Cord Blood Corporation

      Global Cord Blood Corporation is the first and largest umbilical cord blood banking operator in China in terms of geographical coverage and the only cord blood banking operator with multiple licenses. Global Cord Blood Corporation provides cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. For more information, please visit the Company's website at:
      http://www.globalcordbloodcorp.com.  

      Safe Harbor Statement

      This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These statements relate to future events or the Company's future financial performance. The Company has attempted to identify forward-looking statements by terminology including "anticipates", "believes", "expects", "can", "continue", "could", "estimates", "intends", "may", "plans", "potential", "predict", "should" or "will" or the negative of these terms or other comparable terminology. These statements are only predictions, uncertainties and other factors may cause the Company's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. The information in this press release is not intended to project future performance of the Company. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company does not guarantee future results, levels of activity, performance or achievements. The Company expectations are as of the date this press release is issued, and the Company does not intend to update any of the forward-looking statements after the date this press release is issued to conform these statements to actual results, unless required by law.

      The forward-looking statements included in this press release are subject to risks, uncertainties and assumptions about the Company's businesses and business environments. These statements reflect the Company's current views with respect to future events and are not a guarantee of future performance. Actual results of the Company's operations may differ materially from information contained in the forward-looking statements as a result of risk factors some of which include, among other things: the ongoing impact of COVID-19, including the partial lockdowns implemented in various cities in the PRC and the imposition by some hospitals in the PRC of restrictions on entrance to solely to hospital staff and patients; levels of consumer confidence in the healthcare services sector generally in the PRC as a result of the outbreak; the length of the COVID-19 outbreak and severity of such outbreak across the globe; the pace of recovery following the COVID-19 outbreak; continued compliance with government regulations regarding cord blood banking in the People's Republic of China, or PRC and any other jurisdiction in which the Company conducts its operations; changing legislation or regulatory environments in the PRC (including but not limited to cord blood license related regulations, Biosecurity laws, antitrust laws) and any other jurisdiction in which the Company conducts its operations; the acceptance by subscribers of the Company's different pricing and payment options and reaction to the introduction of the Company's premium-quality pricing strategy; demographic trends in the regions of the PRC in which the Company is the exclusive licensed cord blood banking operator; labor and personnel relations; the existence of a significant shareholder able to influence and direct the corporate policies of the Company; credit risks affecting the Company's revenue and profitability; changes in the healthcare industry, including those which may result in the use of stem cell therapies becoming redundant or obsolete; the Company's ability to effectively manage its growth, including maintaining effective controls and procedures and attracting and retaining key management and personnel; changing interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of legislative developments in the U.S. affecting listed issuers whose independent registered public accounting firms are based in China and not subject to U.S. Public Company Accounting Oversight Board inspections, international pressure on trade and currency against the PRC and its potential impact on the PRC consumer behavior, as well as general economic conditions, the non-binding proposal letter from Alternate Ocean and the potential transaction contemplated by such letter, and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission in the United States.

      This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the period ending September 30, 2021 were made at the noon buying rate of RMB6.4434 to $1.00 on September 30, 2021 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. Global Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.

      EXHIBIT 1


      GLOBAL CORD BLOOD CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

      As of March 31 and September 30, 2021



      March 31,


      September 30,


      2021


      2021


      RMB


      RMB


      US$


      (in thousands except share data)

      ASSETS






      Current assets






      Cash and cash equivalents

      6,075,798


      6,390,632


      991,812

      Accounts receivable, less allowance for credit losses






        (March 31, 2021: RMB137,961; September 30, 2021:      






        RMB150,060 (US$23,289))

      130,298


      144,667


      22,452

      Inventories

      44,257


      33,821


      5,250

      Prepaid expenses and other receivables 

      47,788


      79,343


      12,313

      Total current assets

      6,298,141


      6,648,463


      1,031,827

      Property, plant and equipment, net

      498,656


      484,434


      75,183

      Operating lease right-of-use assets

      5,039


      3,969


      616

      Non-current deposits 

      344,752


      343,529


      53,315

      Non-current accounts receivable, less allowance for credit 






        losses (March 31, 2021: RMB67,095; September 30,






        2021: RMB62,544 (US$9,707))

      217,208


      241,377


      37,461

      Inventories

      91,446


      93,261


      14,474

      Intangible assets, net

      88,202


      85,892


      13,330

      Investment in equity securities at fair value

      117,911


      108,974


      16,912

      Other equity investment

      189,129


      189,129


      29,352

      Deferred tax assets

      55,845


      59,230


      9,192

      Total assets

      7,906,329


      8,258,258


      1,281,662







      LIABILITIES






      Current liabilities






      Accounts payable

      9,479


      13,442


      2,086

      Accrued expenses and other payables

      136,448


      153,872


      23,880

      Operating lease liabilities

      1,636


      1,675


      260

      Deferred revenue

      449,359


      451,022


      69,998

      Income tax payable

      29,547


      30,767


      4,775

      Total current liabilities

      626,469


      650,778


      100,999

      Non-current deferred revenue

      2,392,906


      2,441,499


      378,915

      Non-current operating lease liabilities

      147


      50


      8

      Other non-current liabilities

      482,224


      495,826


      76,951

      Deferred tax liabilities

      16,132


      16,701


      2,592

      Total liabilities

      3,517,878


      3,604,854


      559,465







      EQUITY






      Shareholders' equity of Global Cord Blood






        Corporation






      Ordinary shares






      -   US$0.0001 par value, 250,000,000 shares authorized, 






          121,687,974 and 121,551,075 shares issued and 






          outstanding as of March 31 and September 30, 2021, 






         respectively

      83


      83


      13

      Additional paid-in capital

      2,101,582


      2,101,582


      326,161

      Treasury stock, at cost (March 31 and September 30,






          2021: 136,899 shares, respectively)

      (2,815)


      (2,815)


      (437)

      Accumulated other comprehensive losses

      (103,179)


      (105,354)


      (16,351)

      Retained earnings

      2,386,187


      2,648,344


      411,016

      Total equity attributable to Global Cord Blood  






        Corporation

      4,381,858


      4,641,840


      720,402

      Non-controlling interests

      6,593


      11,564


      1,795

      Total equity

      4,388,451


      4,653,404


      722,197

      Total liabilities and equity

      7,906,329


      8,258,258


      1,281,662

       

       

      EXHIBIT 2


      GLOBAL CORD BLOOD CORPORATION

      UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

      For the Three Months and Six Months Ended September 30, 2020 and 2021




      Three months ended September 30,


      Six months ended September 30,



      2020


      2021


      2020


      2021



      RMB


      RMB


      US$


      RMB


      RMB


      US$



      (in thousands except per share data)














      Revenues


      285,607


      313,670


      48,681


      566,520


      628,844


      97,595

      Cost of revenues


      (44,698)


      (46,209)


      (7,172)


      (88,161)


      (94,050)


      (14,596)

      Gross profit


      240,909


      267,461


      41,509


      478,359


      534,794


      82,999

      Operating expenses













      Research and development


      (4,953)


      (5,573)


      (865)


      (9,298)


      (10,671)


      (1,656)

      Sales and marketing


      (54,124)


      (56,924)


      (8,834)


      (109,184)


      (116,327)


      (18,054)

      General and administrative


      (42,671)


      (44,512)


      (6,908)


      (87,207)


      (90,788)


      (14,090)

      Total operating expenses


      (101,748)


      (107,009)


      (16,607)


      (205,689)


      (217,786)


      (33,800)

      Operating income


      139,161


      160,452


      24,902


      272,670


      317,008


      49,199

      Other income/(expenses), net













      Interest income


      8,810


      7,989


      1,240


      15,577


      16,179


      2,511

      Foreign currency exchange 













        gains/(losses)


      66


      (15)


      (2)


      108


      131


      20

      Change in fair value of equity













        securities


      5,699


      (12,616)


      (1,958)


      24,104


      (7,015)


      (1,089)

      Dividend income


      1,281


      -


      -


      1,281


      1,120


      174

      Others


      1,195


      583


      90


      2,918


      1,222


      190

      Total other income/(expenses), 













        net


      17,051


      (4,059)


      (630)


      43,988


      11,637


      1,806

      Income before income tax 


      156,212


      156,393


      24,272


      316,658


      328,645


      51,005

      Income tax expense


      (22,890)


      (28,251)


      (4,384)


      (48,911)


      (61,517)


      (9,547)

      Net income


      133,322


      128,142


      19,888


      267,747


      267,128


      41,458

      Net income attributable to 













      non-controlling interests


      (1,888)


      (2,406)


      (373)


      (3,804)


      (4,971)


      (772)

      Net income attributable to 













      Global Cord Blood Corporation's













      Shareholders


      131,434


      125,736


      19,515


      263,943


      262,157


      40,686














      Earnings per share:













      Attributable to ordinary shares













      -   Basic


      1.08


      1.03


      0.16


      2.17


      2.15


      0.33

      -   Diluted


      1.08


      1.03


      0.16


      2.17


      2.15


      0.33














      Other comprehensive losses, net  












       of nil income taxes 













      -  Foreign currency translation













        adjustments


      (4,202)


      (229)


      (36)


      (4,641)


      (2,175)


      (338)

      Comprehensive income


      129,120


      127,913


      19,852


      263,106


      264,953


      41,120














      Comprehensive income attributable to 












      non-controlling interests


      (1,888)


      (2,406)


      (373)


      (3,804)


      (4,971)


      (772)

      Comprehensive income 













      attributable to Global Cord Blood













      Corporation's shareholders


      127,232


      125,507


      19,479


      259,302


      259,982


      40,348

      EXHIBIT 3


      GLOBAL CORD BLOOD CORPORATION

      RECONCILIATION OF NON-GAAP OPERATING INCOME

      For the Three Months and Six Months Ended September 30, 2020 and 2021




      Three months ended 


      Six months ended 



      September 30,


      September 30,



      2020


      2021


      2020


      2021



      RMB


      RMB


      US$


      RMB


      RMB


      US$



      (in thousands)

      GAAP amount of operating













        income


      139,161


      160,452


      24,902


      272,670


      317,008


      49,199

      Depreciation and amortization













        expenses[4]


      12,266


      12,370


      1,920


      24,622


      24,265


      3,765

      Non-GAAP operating













        income


      151,427


      172,822


      26,822


      297,292


      341,273


      52,964


      [4] Depreciation and amortization expenses relate to property, plant and equipment and intangible assets respectively.

      SOURCE Global Cord Blood Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.